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Abstract: Outbreaks of Bacillus anthracis in the US and Europe over the past 10 years 
have emphasized the health threat this lethal bacteria poses even for developed parts of the 
world. In contrast to cutaneous anthrax, inhalational disease in the US during the 2001 
outbreaks and the newly identified injectional drug use form of disease in the UK and 
Germany have been associated with relatively high mortality rates. One notable aspect of 
these  cases  has  been  the  difficulty  in  supporting  patients  once  shock  has  developed. 
Anthrax bacilli produce several different components which likely contribute to this shock. 
Growing  evidence  indicates  that  both  major  anthrax  toxins  may  produce  substantial 
cardiovascular dysfunction. Lethal toxin (LT) can alter peripheral vascular function; it also 
has  direct  myocardial  depressant  effects.  Edema  toxin  (ET)  may  have  even  more 
pronounced peripheral vascular effects than LT, including the ability to interfere with the 
actions of conventional vasopressors. Additionally, ET also appears capable of interfering 
with  renal  sodium  and  water  retention.  Importantly,  the  two  toxins  exert  their  actions  
via  quite  different  mechanisms  and  therefore  have  the  potential  to  worsen  shock  and 
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outcome in an additive fashion. Finally, both toxins have the ability to inhibit host defense 
and microbial clearance, possibly contributing to the very high bacterial loads noted in 
patients dying with anthrax. This last point is clinically relevant since emerging data has 
begun to implicate other bacterial components such as anthrax cell wall in the shock and 
organ injury observed with infection. Taken together, accumulating evidence regarding the 
potential contribution of LT and ET to anthrax-associated shock supports efforts to develop 
adjunctive therapies that target both toxins in patients with progressive shock. 
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1. Introduction  
Although  the  cutaneous  form  of  Bacillus  anthracis  infection  is  most  common  worldwide, 
inhalational and gastrointestinal anthrax, as well as the recently recognized soft tissue infection in 
injection drug users, termed injectional anthrax, are more lethal [1–3]. Death in these latter three is 
almost  always  preceded  by  progressive  hemodynamic  instability  and  shock.  Compared  to  more 
commonly encountered types of bacteria, shock with anthrax appears to be potentially more resistant to 
conventional types of hemodynamic support. In the 2001 US outbreak of anthrax, all patients who 
developed shock died despite aggressive intensive care unit support. While the number of patients 
involved in this outbreak was small, a mortality rate of 100% is much greater than typically reported 
for other types of treated bacterial shock [4]. Similarly, patients who developed shock in the recent UK 
anthrax outbreak among injection drug users have also been reported to be more difficult to manage 
with standard hemodynamic support [5]. 
While B. anthracis produces several components which may play an important role in shock, its 
two exotoxins, lethal toxin (LT) and edema toxin (ET), have received particular attention. Past and 
recent work directed at the cardiovascular effects of LT and ET provides important insights into the 
pathogenesis and potential management of shock with anthrax. Here, we review some of that work, 
and also briefly consider other components of B. anthracis that might contribute to shock.  
2. Lethal and Edema Toxin Structure and Intracellular Effects 
Lethal and edema toxins are A-B type exotoxins composed of 2 proteins each, the A component 
being either lethal factor (LF) and/or edema factor (EF), respectively, and the B component, common 
to both, being protective antigen (PA). Following infection, PA released into the circulation binds to 
host cell surface receptors such as tumor endothelial marker 8 (TEM8) or capillary morphogenesis 
gene 2 (CMG2) [6–9]. Possibly most highly expressed in endothelial cells, both receptors have been 
demonstrated in a range of tissues including heart, lung, small intestine, spleen liver, kidney, skeletal 
muscle, and skin [10,11].  
By itself, PA does not appear to have pathologic effects on the host [12]; its importance lies in its 
ability to facilitate intracellular delivery of the toxic anthrax factors (LF and EF). Upon binding to 
receptors, the 83 kD PA molecules undergo furin cleavage into 20 kD portions (freed into extracellular Toxins 2011, 3                                       
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space), and 63 kD subunits that remain cell surface bound and combine to produce heptamers [13,14]. 
One to three LF and/or EF subunits competitively bind to these heptamers forming complexes, which 
undergo endocytosis and progressive acidification, after which EF and LF are released intracellularly [15].  
Lethal factor is a zinc metalloprotease that inactivates mitogen-activated protein kinase kinases 
(MAPKK) 1–4, 6 and 7. While LF has been demonstrated to cause lysis of macrophages in vitro [6,16] 
and inhibit important host cell functions (e.g., innate and adaptive immunity and apoptosis), how it 
contributes to death associated with LT is still unclear. Edema factor is a calmodulin-dependent adenyl 
cyclase that increases intracellular cAMP concentration and impairs host defenses, including inhibition 
of phagocytosis [6,17,18]. It causes edema when injected subcutaneously into experimental animals [19]. 
Recent reviews as well as other contributions in this issue provide comprehensive overviews of the 
likely intracellular effects of LF and EF [16,18,20]. 
While older studies suggested that LT was the key virulence factor required for the lethal effects of 
B. anthracis, more recent studies have emphasized the potential importance of ET [12,21–23]. Both LT 
and ET are capable of producing cardiovascular effects leading to shock, and given their different 
actions, the combination of both toxins in active infection has potentially additive effects on increasing 
the severity of anthrax-associated shock.  
3. Lethal Toxin 
Lethal toxin has been a focus of research since its original description as a bacterial component 
closely associated with death due to anthrax [24,25]. Shortly after the original description of LT in the 
1950’s, a small number of studies in guinea pigs, rats and rhesus monkeys administered LT as a bolus, 
suggested  that  this  toxin  caused  extravasation  of  fluid,  hemoconcentration  and  shock  [26–29]. 
However, based on limited measures of cardiac and pulmonary function, it was concluded that this 
shock was a terminal event related in part to respiratory failure [8]. Over the 30 years following these 
early  investigations,  no  additional  studies  characterizing  the  cardiopulmonary  effects  of  LT  were 
reported. However, in  contrast  to  findings  from these early studies  with  LT, during the 2001  US 
anthrax outbreak, shock occurred well before death in non-survivors and did not initially appear to 
result from respiratory failure [1]. Similarly, shock has been a primary event noted in the UK anthrax 
outbreak in injection drug users [5]. 
In vivo studies from several laboratories over the past 5 to 10 years, while employing differing 
species, toxin challenges and methods of measure, together suggest that LT does indeed produce shock 
and organ injury directly, and that the underlying physiologic mechanisms are likely multifactorial. 
Based on the pattern of histological injury noted in mice challenged with LT as an intraperitoneal 
bolus, Moayeri et al. concluded that lethality with LT was related to tissue hypoxia such as would 
occur with organ hypoperfusion [30]. In rats with indwelling central venous and arterial catheters, we 
found  that  24  h  LT  infusions  produced  progressive  hypotension  that  was  significantly  greater  in 
animals  that  later  died  [31].  These  changes  were  associated  with  evidence  of  hemoconcentration  
(i.e., increased hemoglobin concentrations) and tissue hypoperfusion (i.e., increased lactate levels). In 
subsequent  studies  with  sedated  and  mechanically  ventilated  canines  with  invasive  hemodynamic 
monitoring, 24-h LT infusions also caused progressive shock and reductions in central venous pressure 
over the subsequent 72 h observation period (Figure 1) [23]. These findings are consistent with a Toxins 2011, 3                                       
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potential effect of LT on the peripheral vasculature; several groups have reported that LT can disrupt 
endothelial barrier function. Stimulation of endothelial cell apoptosis, alteration of actin fibers and 
cadherins and mast cell activation are invoked as possible mechanisms causing endothelial dysfunction 
from in vitro experiments [32–36]. In addition, work in a zebrafish model has implicated LT disruption 
of MAPKKs in endothelial dysfunction [37,38]. The time course of endothelial changes from in vitro 
studies is consistent with the gradual onset of clinical changes noted in the canine model. Interestingly 
though, in rat and canine models, LT challenge was not associated with pleural effusions like those 
noted in humans with anthrax infection [1]. This finding suggests that other factors, possibly working 
in combination with LT, are necessary for this manifestation of active infection.  
In addition to its potential effects on the peripheral vasculature, there is evidence to suggest that LT 
may directly depress myocardial function. We found that in sedated, mechanically ventilated canines, 
progressive  hypotension  occurred,  and  left  ventricular  ejection  fraction  (LVEF)  measured  with 
echocardiography also progressively decreased from 48 to 96 h after initiating a 24 h LT infusion in 
doses producing low (n = 6) or high (n = 9) lethality rates compared to a control group (n = 9)  
(Figure 1) [23]. Pulmonary artery occlusion pressure was not reduced, suggesting that decreases in 
preload were not the primary basis for hypotension or reduced LVEF. Heart rate did increase over 
time, and cardiac output was maintained (Figure 1). Other labs have also noted myocardial effects of 
LT. Watson et al assessed myocardial function with echocardiography in rats administered injections 
of LT producing hypotension and lethality [39,40]. They noted that 1–2 h after challenge, LT increased 
velocity of propagation and left ventricular diastolic and systolic areas [39]. In another report, the same 
authors  noted  that  by  18  h  after  challenge,  LT  also  increased  left  ventricular  systolic  area  and 
decreased  velocity  of  propagation,  circumferential  fiber  shortening  and  left  ventricular  ejection 
fraction  [40].  In  a  subsequent  abstract  and  review,  the  group  went  on  to  describe  an  experiment 
employing pressure-volume loop measures in canines where, compared to controls, LT injection in  
2 animals was associated with reduced stroke volume, end systolic pressure and ejection fraction, and 
increased left ventricular end diastolic pressure (LVEDP), in an overall pattern consistent with severe 
heart failure by 96 h after challenge [41]. Consistent with these findings, Moayeri et al. reported that 
intraperitoneal LT challenge in mice was associated with reduced LVEF and myocardial changes on 
electron microscopy as early as 6 h [42]. Although the mechanisms underlying the potential myocardial 
effects of LT are not clear, inhibition of MAPK ERK1/2 has been shown to produce stress-induced 
apoptosis and heart failure, whereas augmentation is protective [43–45]. Also, a recent in vitro study 
has  suggested  that  LT  may  depress  cardiomyocyte  function  via  an  NADPH  oxidase-dependent 
mechanism [46].  
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Figure  1.  Continuously  sedated  and  mechanically  ventilated  canines  with  indwelling 
systemic and pulmonary arterial catheters were challenged with 24 h infusions of low or 
high doses of lethal toxin (LT) or diluent only (controls) [23]. Panels A through D show 
the serial mean (± SEM) effects compared to controls of the two doses of LT on changes 
from  baseline  for  mean  arterial  blood  pressure  (MAP,  mmHg),  heart  rate  (HR,  bpm), 
central venous pressure (CVP, mmHg), and left ventricular ejection fraction (LVEF, %). 
The shaded gray area denotes the 24 hour toxin infusion period. Increases or decreases 
with  toxin  compared  to  controls  are  denoted  by  symbols  above  or  below  the  dashed 
horizontal no effect line, respectively. The p statistics are shown in each panel for the 
overall effect of toxin compared to control (p
α) and the interaction between time and the 
effect  of toxin  (p
β). For statistical  analysis serial  changes  from  baseline with  LT were 
compared to serial changes from baseline in controls. However, for clarity in this figure the 
serial effects of challenge (i.e., toxin minus control) are shown. Overall, MAP, CVP and 
LVEF decreased while HR increased with LT compared to controls.  
 
Despite the cardiac effects of LT noted in  in vivo models, using an isolated perfused rat heart 
system observed over a 4 h period we were only able to document a direct effect of LT on myocardial 
function with toxin doses substantially higher than those producing shock and lethality in vivo [22]. Toxins 2011, 3                                       
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This, in combination with the in vivo studies, suggests that the effects of LT on myocardial function 
may take at the least several hours to develop. It is also possible that peripheral vascular changes and 
resulting hypotension may aggravate myocardial changes seen in in vivo models. In our canine model, 
although  pulmonary  arterial  occlusion  pressure  (PAOP)  was  not  reduced,  central  venous  pressure 
(CVP) was, and fluid loading increased LVEF to some degree [23].  
Figure 2. Effects of sublethal doses of lethal toxin (LT) compared to placebo administered 
3  h  before  intravenous  lipopolysaccharide  (LPS)  or  intratracheal  E.  coli  challenge  on 
plasma cytokine levels (panel A), mean arterial blood pressure (MAP, panel B) and the 
hazard ratio of survival (panel C) [47]. Cytokines were measured at 2, 8 and 24 h; blood 
pressure was averaged over the 24 h after challenge; and survival was assessed at 168 h. 
With  both  LPS  and  E.  coli,  LT  had  variable  effects  on  cytokines  at  2  and  24  h  but 
uniformly reduced all 13 at 8 h. The consistent decreases caused by LT in all cytokines at  
8 h were significantly different from the more variable changes noted at 2 and 24 h with 
both challenges (p = 0.001 and 0.02 as shown in Panel A). These anti-inflammatory effects 
of sublethal LT were associated with higher than control MAP and survival with  LPS 
challenge. However, with E. coli the effects were significantly different; increases in MAP 
were smaller and survival was actually reduced.  
 Toxins 2011, 3                                       
 
 
1191 
Finally,  LT’s  contribution  to  the  development  of  shock  may  also  involve  its  apparent 
immunosuppressive effects. Cardiovascular dysfunction during severe bacterial infection is thought to 
relate in part to the damaging effects of inflammatory mediators (e.g., cytokines, nitric oxide, oxygen 
free radicals) produced by the host during the innate immune response. One report suggested that 
macrophage damage by LT might produce increased circulating inflammatory cytokine levels, and that 
macrophage inhibition was beneficial with lethal doses of LT [48]. Subsequent studies however have 
not found a clear association between the cardiovascular dysfunction produced by LT and excessive 
inflammatory mediator production [8,12,30,31]. Such findings are consistent with LF’s known effect 
on suppressing stress kinase pathways, which are typically important contributors to the inflammatory 
response during infection [16,20,49]. In fact, we found in a rat model that pretreatment of animals  
with  a  sub-lethal  dose  of  LT  actually  blunted  the  inflammatory  response  stimulated  by  either 
lipopolysaccharide (LPS) or intratracheal E. coli challenges (Figure 2) [47]. Notably however, while 
pretreatment with LT increased survival with LPS, it reduced survival with E. coli. Therefore, as has 
been suggested by other investigators, LT may also participate in the pathogenesis of shock and organ 
injury during anthrax infection by suppressing host microbial clearance and contributing to the very 
high bacterial loads noted in subjects dying with infection [49].  
4. Edema Toxin 
ET has received considerably less attention than LT since mutant deletion studies as well as direct 
comparisons  of  the  two  toxins  suggested  that  the  latter  played  a  more  central  role  in  anthrax 
pathogenesis [50]. A study in rabbits suggested that LT may be produced in greater proportion than ET 
during active infection [51]. We reported that when administered as 24 h infusions, on a molar dose 
basis, LT was 5 to 20 fold more lethal than ET in both rats and canines [12,23]. In addition, efforts to 
generate large quantities of purified EF from B. anthracis cultures proved difficult, resulting in low 
yields and high levels of contaminating proteins [52]. Despite such data, there are still reasons to 
believe that ET plays an important role in the pathogenesis of shock during anthrax. Furthermore, 
recent  developments  allowing  the  generation  of  recombinant  EF  from  cultures  of  E.  coli  have 
demonstrated consistently large quantities of >97% pure EF [53], mitigating previous concerns that the 
degree of purity of some edema factor preparations may skew the interpretation of cell culture or  
in vivo data. 
From its first description and as its name implies, ET was noted for its ability to promote local 
extravasation of fluid [25]. Clinically, the notable extravascular fluid collections, such as the pleural 
effusions observed during the 2001 US outbreak, suggested that ET might play an important role in 
systemic infection [54]. Some patients in the recent UK outbreak also demonstrated striking soft tissue 
edema, not only locally at the sites of initial infection, but at more distant sites as well [5]. Finally,  
we noted that mortality from LT challenge increased in both rat and canine models when LT was  
co-administered with equimolar but nonlethal doses of ET [12,23].  
While the mechanisms underlying shock with LT appear to be multifactorial and thus have been 
difficult to delineate, those underlying ET’s possible role may be easier to understand. ET has potent 
calmodulin dependent adenylcyclase activity, estimated to be 1000 times greater than that associated 
with eukaryotic adenylcyclases [17]. In vitro, ET increases intracellular cAMP to very high levels; Toxins 2011, 3                                       
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cAMP  is  a  key  in  mediator  of  vasodilation  of  both  arteries  and  veins  [55,56].  We  noted  rapid 
reductions in both central venous and arterial blood pressure in canines in patterns that persisted for up 
to 72 h after challenge with 24 h ET infusions, using doses causing high or low mortality (Figure 3) [23]. 
In a rat model, non-lethal and lethal ET infusions also produced rapid, persistent reductions in blood 
pressure [12]. Notably in both rat and canine studies, ET infusion was not associated with evidence of 
hemoconcentration (i.e., circulating hemoglobin concentrations were not increased) or extravascular 
fluid  collections  (e.g.,  pleural  effusions  or  ascites),  suggesting  that  reductions  in  central  venous 
pressure (CVP) might in part represent relaxation of venous capacitance vessels. In both models, ET 
caused tachycardia that appeared to be out of proportion to other hemodynamic changes, but was 
consistent with increased cAMP in cardiac pacemaker cells (Figure 3) [57,58]. Echocardiography also 
demonstrated  evidence  of  reduced  preload  in  rats  administered  a  rapid  ET  challenge  by  other 
investigators, although no extravasation of fluid was noted on lung pathology. 
Figure  3.  Continuously  sedated  and  mechanically  ventilated  canines  with  indwelling 
systemic and pulmonary arterial catheters were challenged with 24 h infusions of low or 
high doses of edema toxin (ET) or diluent alone (controls) [23]. Panels A through C show 
the serial mean (± SEM) effects compared to controls of the two doses of ET on changes 
from baseline for mean arterial blood pressure (MAP, mmHg), heart rate (HR, bpm), and 
central venous pressure (CVP, mmHg). The format and presentation of data is similar to 
Figure 1. Challenge with 24 h ET infusions in canines using both high and low doses of 
toxin produced rapid reductions in both central venous and arterial blood pressure and 
increases in heart rate that persisted for up to 72 h after challenge. 
 
In a perfused rat heart model that is free of preload and after-load influences, we found that ET 
challenge, in addition to producing significant tachycardia, caused substantial increases in coronary 
flow rate consistent with a direct vasodilatory effect of the toxin [22]. Interestingly, in this isolated 
system, ET also had inotropic effects (Figure 4). While these effects were transient with higher ET 
doses, they persisted at lower ones. Consistent with its predominant mechanism of action, ET produced 
increases in both myocardial tissue and effluent cAMP levels (Figure 5). Adefovir, a nucleoside agent 
which  has  been  shown  to  inhibit  EF  adenylcyclase  activity  in  vitro  [59],  inhibited  ET  associated Toxins 2011, 3                                       
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increases  in  heart  rate  (HR),  coronary  flow  and  cAMP  levels  (Figure  5).  Given  its  effect  on 
intracellular cAMP, ET may be a potential cause of the vasopressor resistant shock noted in patients in 
both the U.S. and U.K. outbreaks [5], since such agents can blunt the vasoconstrictive effects of agents 
like norepinephrine and phenylephrine.  
Figure 4. The difference in change from baseline from controls (no toxin) is shown as 
serial effects (mean ±  SEM) of three doses of edema toxin (ET, 50, 100, and 200 ng/mL) 
on  heart  rate  (HR),  coronary  flow,  left  ventricular  developed  pressure  (LVDP),  rate 
pressure product (RPP), and left ventricular dP/dt max and dP/dt min in a non-recirculating 
isolated rat heart model [22]. The shaded area represents when toxin was administered. The  
p statistics are shown for the overall effects of toxin versus control (p
α), and the interaction 
between these effects and time (p
β). For statistical analysis serial changes from baseline 
with edema toxin were compared to serial changes from baseline in controls. However, for 
clarity in this figure, the serial effects of challenge (i.e., toxin minus control) are shown.  
In the model, ET challenge produced significant tachycardia, caused substantial increases 
in coronary flow rate consistent with a direct vasodilatory effect of the toxin, and had 
inotropic effects that were transient with higher ET doses but persistent at lower ones. 
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Figure 5. Panels A and B show the serial effects (mean ±  SEM) of edema toxin (ET) with 
or without adefovir compared to controls on heart rate (HR) (Panel A) and coronary flow 
(Panel  B) in  a recirculating, constant  pressure,  isolated, perfused  rat  heart model [22]. 
Hearts  were  exposed  to  toxin  and  treatment  throughout  the  perfusion  period.  The  p 
statistics  are  shown  for  the  overall  effects  of  toxin  with  placebo  versus  with  adefovir 
compared to control (no toxin) (p
α), and the interaction between these effects and time (p
β). 
For  statistical  analysis  serial  changes  from  baseline  with  edema  toxin  with  or  without 
adefovir were compared to serial changes from baseline in controls. However, for clarity in 
this figure the serial effects of edema toxin alone or with treatment (i.e., toxin with or 
without adefovir minus control) are shown. Panel C shows mean (± SEM) cAMP levels in 
myocardial tissue 30 min after completion of an hour of perfusion with PA alone, edema 
toxin (ET) alone, or edema toxin with adefovir. Panel D shows serial mean (± SEM) cAMP 
levels in effluent from hearts perfused for 60 min with PA alone, ET alone, or ET with 
adefovir.  The  shaded  area  denotes  the  time  of  toxin  infusion.  Consistent  with  its 
predominant mechanism of action, ET produced increases in both myocardial tissue and 
effluent cAMP levels that were inhibited by adefovir, a nucleoside agent which has been 
shown to inhibit EF adenylcyclase activity in vitro. 
 Toxins 2011, 3                                       
 
 
1195 
Additionally, we noted in our canine model that even as shock developed, ET challenge resulted in 
ten-fold increases in urine output, along with decreased serum sodium (Figure 6) [23]. Since increased 
tubular cAMP stimulated by other types of toxins (e.g., cholera toxin) is associated with inappropriate 
sodium and water losses, it is possible that similar mechanisms may aggravate shock in patients with 
anthrax  [60–62].  Of  note,  hyponatremia  has  been  a  frequently  reported  abnormality  in  patients 
presenting with anthrax [63]. Furthermore, in a murine model, ET was associated with adrenal gland 
necrosis, which could also aggravate sodium and water losses [21]. 
Figure  6.  Continuously  sedated  and  mechanically  ventilated  canines  with  indwelling 
systemic and pulmonary arterial catheters were challenged with 24 h infusions of low or 
high  doses  of  edema  toxin  (ET)  or  diluent  alone  (controls)  [23].  Panels  A  and  B, 
respectively, show the serial mean (± SEM) effects compared to controls of the two doses 
of ET on 24 h rates of urine output (mL/kg/24 h) and on the changes from baseline in 
serum sodium  (Na) levels. The format and presentation  of data is  similar to  Figure 1. 
Despite the development of shock in the model, ET challenge resulted in ten-fold increases 
in urine output and decreased serum sodium, suggesting that inappropriate sodium and 
water losses may aggravate shock in patients with anthrax. 
 
Like  LT,  ET  may  also  have  immunosuppressive  effects.  Challenge  with  ET  alone  does  not 
stimulate the typical inflammatory mediator release noted with most types of bacterial infection [47]. 
Furthermore, ET has been shown to alter several different aspects of host defense, including reduced 
activation and function of antigen-presenting cells, increased release of cytokines from dendritic cells, 
and impaired chemotaxis and differentiation of T lymphocytes [49].  
Although on a molar dose basis ET is less lethal than LT and the production of LT may be greater 
than ET during infection, the two toxins together may have synergistic effects [12,51]. In mouse, rat 
and canine models, nonlethal ET doses have been shown to add to the lethality of LT dose [12,23,64]. 
The basis for such synergy is not  clear. ET has been shown to up-regulate the expression of PA 
receptors  on  macrophages  and  dendritic  cells  in  vitro,  thereby  increasing  the  rate  of  toxin Toxins 2011, 3                                       
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internalization [65]. ET has also been shown to potentiate the inhibitory effects of LT on T-cell and 
dendritic cell function and chemotaxis [66,67]. 
5. Other Components that May Aggravate Toxin Associated Shock 
Although LT and ET have been the focus of research as pathogenic products of B. anthracis, other 
components of this organism such as bacterial cell wall and several metalloproteinases may also be 
important. In contrast to lethal or shock-inducing doses of LT or ET, challenge with live B. anthracis 
organisms does stimulate inflammatory mediator release [68–71]. As with other types of sepsis, this 
inflammation may contribute to shock and organ injury with anthrax.  
There is evidence suggesting that B. anthracis cell wall may stimulate this inflammatory response. 
Human peripheral blood mononuclear cells, possibly via stimulation of TLR2/6 heterodimers, release 
TNFα, IL-1β and IL-6 in response to challenge with whole B. anthracis cell wall [72,73]. Anthrax 
infection  in  vitro  also  results  in  NOD-2  dependent  IL-1β  release  [74].  We  noted  dose  dependent 
increases in lethality, lactate, circulating inflammatory cytokine, chemokine and nitric oxide levels and 
thrombocytopenia when we challenged rats with whole anthrax cell wall [75]. Peptidoglycan appears 
to be the component of the cell wall largely responsible for its immuno-stimulatory effects, and in fact, 
peptidoglycan is shed by replicating bacteria [76,77]. This ability of anthrax cell wall to produce a 
robust  intravascular  inflammatory  response  and  participate  in  the  pathogenesis  of  shock  could  be 
important; patients and animals dying with anthrax have very high bacterial loads providing a reservoir 
of active cell wall constituents [73,77].  
Besides LF, B. anthracis also produces proteases that may be important in anthrax infection. The 
delta  Ames  (pXO1
−  and  pXO2
−)  anthrax  strain  produced  metalloproteases  belonging  to  the  M4 
thermolysin and M9 bacterial collagenase families in culture studies [78]. Mice develop hemorrhagic 
tissue injury in response to purified preparations of these proteases. Moreover, animals challenged with 
Sterne strain spores showed better survival if treated with chemical inhibitors or immune serum against 
the  M4  and  M9  proteases  of  B.  anthracis  [78].  Additional  studies  of  homologue  proteases  have 
implicated  them  in  other  pathophysiologic  effects,  including  the  interruption  of  tight  junctions  in 
Vibrio  cholerae  infections,  and  the  cleavage  of  antitrypsin-1α,  TNF-α  and  IL-2  on  human  T  cell 
surfaces in Legionella infections [79,80].  
6. Conclusions  
Both LT and ET have the ability to produce significant cardiovascular dysfunction at either the 
peripheral vascular or myocardial levels, or both. The ability of ET to also potentially interfere with 
renal sodium retention could aggravate the direct cardiovascular effects of either toxin. Importantly, 
both ET and LT likely exert their cardiovascular effects via very different and potentially additive 
mechanisms;  some  in  vivo  data  suggests  that  such  additive  effects  are  indeed  the  case  [12,23]. 
Therefore, utilization of adjunctive agents with the ability to inhibit the two toxins together may very 
well be needed in patients progressing to shock despite appropriate antibiotic therapy and aggressive 
hemodynamic support. Historically, antibodies to individual components of the bacteria were used 
even  before  antibiotic  therapy  was  available  [81].  Two  PA  directed  antibody  preparations,  one 
polyclonal  (Anthrax  Immune  Globulin,  Cangene  Corporation,  Winnipeg,  ME,  Canada)  and  one Toxins 2011, 3                                       
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monoclonal (Raxibacumab, Human Genome Sciences, Inc., Rockville, MD), have been made available 
in recent outbreaks or added to the U. S. Strategic National Stockpile [82–85]. However, while in vitro 
or in vivo data has supported the effectiveness of these agents, their clinical efficacy in humans must 
be clarified. A variety of other types of inhibitors have also been proposed [8,86]. Just as important as 
determining the effectiveness of adjunctive therapies directed against LT and ET is defining how other 
components of the bacteria may contribute to cardiovascular dysfunction during infection. 
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